Walvax Biotechnology Statistics

Total Valuation

Walvax Biotechnology has a market cap or net worth of CNY 20.92 billion. The enterprise value is 20.16 billion.

Market Cap	20.92B
Enterprise Value	20.16B

Important Dates

The next estimated earnings date is Monday, March 31, 2025.

Earnings Date	Mar 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Walvax Biotechnology has 1.60 billion shares outstanding. The number of shares has decreased by -1.45% in one year.

Current Share Class	n/a
Shares Outstanding	1.60B
Shares Change (YoY)	-1.45%
Shares Change (QoQ)	+0.20%
Owned by Insiders (%)	9.03%
Owned by Institutions (%)	16.49%
Float	1.39B

Valuation Ratios

The trailing PE ratio is 170.95 and the forward PE ratio is 40.88.

PE Ratio	170.95
Forward PE	40.88
PS Ratio	6.75
PB Ratio	2.18
P/TBV Ratio	2.45
P/FCF Ratio	128.47
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 28.94, with an EV/FCF ratio of 123.82.

EV / Earnings	164.76
EV / Sales	6.51
EV / EBITDA	28.94
EV / EBIT	57.88
EV / FCF	123.82

Financial Position

The company has a current ratio of 3.10, with a Debt / Equity ratio of 0.06.

Current Ratio	3.10
Quick Ratio	2.69
Debt / Equity	0.06
Debt / EBITDA	1.04
Debt / FCF	4.45
Interest Coverage	35.30

Financial Efficiency

Return on equity (ROE) is 1.41% and return on invested capital (ROIC) is 1.77%.

Return on Equity (ROE)	1.41%
Return on Assets (ROA)	1.42%
Return on Capital (ROIC)	1.77%
Revenue Per Employee	1.30M
Profits Per Employee	51,245
Employee Count	2,388
Asset Turnover	0.20
Inventory Turnover	0.74

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -40.28% in the last 52 weeks. The beta is 0.72, so Walvax Biotechnology's price volatility has been lower than the market average.

Beta (5Y)	0.72
52-Week Price Change	-40.28%
50-Day Moving Average	14.76
200-Day Moving Average	13.58
Relative Strength Index (RSI)	32.43
Average Volume (20 Days)	30,431,560

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Walvax Biotechnology had revenue of CNY 3.10 billion and earned 122.37 million in profits. Earnings per share was 0.08.

Revenue	3.10B
Gross Profit	2.36B
Operating Income	348.36M
Pretax Income	198.54M
Net Income	122.37M
EBITDA	669.52M
EBIT	348.36M
Earnings Per Share (EPS)	0.08

Full Income Statement

Balance Sheet

The company has 3.62 billion in cash and 725.17 million in debt, giving a net cash position of 2.90 billion or 1.81 per share.

Cash & Cash Equivalents	3.62B
Total Debt	725.17M
Net Cash	2.90B
Net Cash Per Share	1.81
Equity (Book Value)	11.73B
Book Value Per Share	6.00
Working Capital	5.01B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 832.24 million and capital expenditures -669.41 million, giving a free cash flow of 162.83 million.

Operating Cash Flow	832.24M
Capital Expenditures	-669.41M
Free Cash Flow	162.83M
FCF Per Share	0.10

Full Cash Flow Statement

Margins

Gross margin is 76.10%, with operating and profit margins of 11.25% and 3.95%.

Gross Margin	76.10%
Operating Margin	11.25%
Pretax Margin	6.41%
Profit Margin	3.95%
EBITDA Margin	21.62%
EBIT Margin	11.25%
FCF Margin	5.26%

Dividends & Yields

This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 0.08%.

Dividend Per Share	0.01
Dividend Yield	0.08%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	23.71%
Buyback Yield	1.45%
Shareholder Yield	1.53%
Earnings Yield	0.58%
FCF Yield	0.78%

Dividend Details

Stock Splits

The last stock split was on October 14, 2015. It was a forward split with a ratio of 3.

Last Split Date	Oct 14, 2015
Split Type	Forward
Split Ratio	3

Scores

Walvax Biotechnology has an Altman Z-Score of 5.83.

Altman Z-Score	5.83
Piotroski F-Score	n/a